Last reviewed 2026-05-14 · How we verify

Dose 1 of QLS1410

Qilu Pharmaceutical Co., Ltd. · Phase 2 active Small molecule

Dose 1 of QLS1410 is a SGLT2 inhibitor Small molecule drug developed by Qilu Pharmaceutical Co., Ltd.. It is currently in Phase 2 development for Type 2 diabetes.

QLS1410 is a small molecule that targets the SGLT2 receptor.

QLS1410 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.

At a glance

Generic name	Dose 1 of QLS1410
Sponsor	Qilu Pharmaceutical Co., Ltd.
Drug class	SGLT2 inhibitor
Target	SGLT2
Modality	Small molecule
Therapeutic area	Diabetes
Phase	Phase 2

Mechanism of action

By inhibiting SGLT2, QLS1410 reduces glucose reabsorption in the kidneys, lowering blood glucose levels. This makes it a potential treatment for type 2 diabetes.

Approved indications

Type 2 diabetes

Common side effects

Increased risk of diabetic ketoacidosis

Key clinical trials

QLS1410 in Participants With Uncontrolled Hypertension (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Dose 1 of QLS1410 CI brief — competitive landscape report
Dose 1 of QLS1410 updates RSS · CI watch RSS
Qilu Pharmaceutical Co., Ltd. portfolio CI

Frequently asked questions about Dose 1 of QLS1410

What is Dose 1 of QLS1410?

Dose 1 of QLS1410 is a SGLT2 inhibitor drug developed by Qilu Pharmaceutical Co., Ltd., indicated for Type 2 diabetes.

How does Dose 1 of QLS1410 work?

QLS1410 is a small molecule that targets the SGLT2 receptor.

What is Dose 1 of QLS1410 used for?

Dose 1 of QLS1410 is indicated for Type 2 diabetes.

Who makes Dose 1 of QLS1410?

Dose 1 of QLS1410 is developed by Qilu Pharmaceutical Co., Ltd. (see full Qilu Pharmaceutical Co., Ltd. pipeline at /company/qilu-pharmaceutical-co-ltd).

What drug class is Dose 1 of QLS1410 in?

Dose 1 of QLS1410 belongs to the SGLT2 inhibitor class. See all SGLT2 inhibitor drugs at /class/sglt2-inhibitor.

What development phase is Dose 1 of QLS1410 in?

Dose 1 of QLS1410 is in Phase 2.

What are the side effects of Dose 1 of QLS1410?

Common side effects of Dose 1 of QLS1410 include Increased risk of diabetic ketoacidosis.

What does Dose 1 of QLS1410 target?

Dose 1 of QLS1410 targets SGLT2 and is a SGLT2 inhibitor.

Drug class: All SGLT2 inhibitor drugs
Target: All drugs targeting SGLT2
Manufacturer: Qilu Pharmaceutical Co., Ltd. — full pipeline
Therapeutic area: All drugs in Diabetes
Indication: Drugs for Type 2 diabetes
Compare: Dose 1 of QLS1410 vs similar drugs
Pricing: Dose 1 of QLS1410 cost, discount & access